United States · FDA National Drug Code directory
Ondansetron
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 65862-390_aab5d8ee-a492-4deb-b240-62b1b0eb0aa8
- Product NDC
- 65862-390
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- Ondansetron
- Labeler
- Aurobindo Pharma Limited
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20100412
- Source listing expiry
- 20261231
Source-listed ingredients
- ONDANSETRON — 4 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (65862-390-02) · 65862-390-02
- 500 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (65862-390-05) · 65862-390-05
- 3 BLISTER PACK in 1 CARTON (65862-390-10) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK · 65862-390-10
- 10000 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (65862-390-19) · 65862-390-19
- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (65862-390-30) · 65862-390-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →